[1] |
WU M, ZHAI S, GAO J, et al. Diagnosis of hepatocellular carcinoma using a novel anti-glycocholic acid monoclonal antibody-based method[J]. Oncol Lett, 2019, 17(3):3103-3112.
DOI
PMID
|
[2] |
SONG W S, PARK H M, HA J M, et al. Discovery of glycocholic acid and taurochenodeoxycholic acid as phenotypic biomarkers in cholangiocarcinoma[J]. Sci Rep, 2018, 8(1):11088.
|
[3] |
中华医学会肝病学分会. 胆汁淤积性肝病管理指南(2021)[J]. 中华肝脏病杂志, 2022, 30(3):253-263.
|
[4] |
ADAMS L A, WANG Z, LIDDLE C, et al. Bile acids associate with specific gut microbiota,low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease[J]. Liver Int, 2020, 40(6):1356-1365.
|
[5] |
MEADOWS V, KENNEDY L, KUNDU D, et al. Bile acid receptor therapeutics effects on chronic liver diseases[J]. Front Med(Lausanne), 2020,7:15.
|
[6] |
LU J, WANG S, LI M, et al. Association of serum bile acids profile and pathway dysregulation with the risk of developing diabetes among normoglycemic chinese adults:findings from the 4C study[J]. Diabetes Care, 2021, 44(2):499-510.
|
[7] |
YIN C, ZHONG R, ZHANG W, et al. The potential of bile acids as biomarkers for metabolic disorders[J]. Int J Mol Sci, 2023, 24(15):12123.
|
[8] |
阚莹, 卢晓华, 孟凡敏, 等. JJF1343-2012《标准物质定值的通用原则及统计学原理》的使用[J]. 中国计量, 2012(11):122-124.
|
[9] |
中国合格评定国家认可委员会. CNAS-GL003 能力验证样品均匀性和稳定性评价指南[S]. 北京: 中国合格评定国家认可委员会, 2018.
|
[10] |
中华人民共和国卫生部. WS/T 356—2011 基质效应与互通性评估指南[S]. 北京: 中华人民共和国卫生部, 2011.
|
[11] |
HUYNH H H, BŒUF A, PFANNKUCHE J, et al. Harmonization status of procalcitonin measurements:what do comparison studies and EQA schemes tell us?[J]. Clin Chem Lab Med, 2021, 59(10):1610-1622.
|
[12] |
CHEN MICHAEL X. 质谱技术在北美临床检验中的应用[J]. 中华检验医学杂志, 2023, 46(8):768-774.
|
[13] |
邹雨桐, 马晓丽, 禹松林, 等. 建立并评价基于LC-MS/MS同时测定脑脊液Aβ1-42、Aβ1-40和Aβ1-38的检测方法[J]. 中华检验医学杂志, 2023, 46(8):814-821.
|
[14] |
黄小亭. 甘氨胆酸候选参考方法的建立与应用[D]. 广州: 广州中医药大学, 2019.
|